Breaking News

BeiGene Earns Merck Serono Milestone

May 5, 2014

BGB-283 BRAF inhibitor achieves clinical milestone

BeiGene, Co. has achieved a clinical milestone in its collaboration with Merck Serono for BGB-283, a second-generation BRAF inhibitor candidate in Phase I development, triggering a $5 million payment from Merck.
 
The companies entered the BGB-283, two-asset strategic collaboration in 2013. In December 2013, BeiGene began a Phase I trial of BGB-283 in patients with BRAF or KRAS mutations. The drug offers the potential to treat cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
 
“We are very pleased to successfully reach this development milestone for BGB-283, as this exciting oncology candidate demonstrates the potential of BeiGene’s innovative translational research platform to deliver targeted therapeutics that address the unmet need of cancer patients,” said John V. Oyler, chief executive officer of BeiGene. “We look forward to working with Merck Serono as it continues to progress through the clinic.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.